NVAX

#2240
Novavax Inc
8.39 USD
+3.45%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
8.39
8.39
Rango anual
5.80
11.97
Cambio diario
+3.45%
Variación mensual
-19.09%
Variación en los últimos 6 meses
-6.15%
Cambio anual
+31.30%
Cierres anteriores
8.11
Abrir
8.39
Bid
Ask
Mínimo
8.39
High
8.39
Volumen
93
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 1.37 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
2.6
Relación precio/flujo de caja
1.04

Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Noticias